CD274 and non-small cell lung carcinoma: First is an open-label monotherapy dose escalation part that aims to determine the MTD and safety of MEM-288 in patients with various advanced cancers, including pancreatic cancer, advanced/metastatic NSCLC, cutaneous squamous-cell carcinoma (cSCC), Merkel cell, melanoma, triple-negative breast cancer (TNBC), or head and neck cancer, who have progressed following antiPD-1/PD-L1 therapy.